Therefore, in recent decades, a lot of researchers [19–21] have paid attention to the therapeutic roles of BRAF inhibitors and MEK inhibitors (a key inhibitor of the MAPK pathway) in BRAF V600E mutant glioma. Here, MAP2K7 is linked to central nervous system cancer.